Abstract: Following the submission of application EFSA-GMO-RX-005 under Regulation (EC) No1829/2003 from Syngenta Crop Protection NV/SA, the Panelon Genetically Modified Organisms of the European Food Safety Authority (GMOPanel) was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application of the herbicide-tolerant genetically modified maizeGA21. The data received in the context of this renewal application contained post-market environmental monitoring reports, a systematic search and evaluation of literature, updated bioinformatics analyses, and additional documents or studies performed by or on behalf of the applicant. The GMO Panelassessed these data for possible new hazards, modified exposure or new scientific uncertainties identified during the authorisation period and not previously assessed in the context of the original application. Under the assumption that the DNA sequence of the event in maize GA21 considered for renewal is identical to the corrected sequence of the originally assessed event, the GMO Panelconcludes that there is no evidence in the renewal application EFSA-GMO-RX-005 for new hazards, modified exposure or scientific uncertainties that would change the conclusions of the original risk assessment on maize GA21. Safety Authority (GMO Panel) was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application of the herbicide-tolerant genetically modified maize GA21. The data received in the context of this renewal application contained post-market environmental monitoring reports, a systematic search and evaluation of literature, updated bioinformatics analyses, and additional documents or studies performed by or on behalf of the applicant. The GMO Panel assessed these data for possible new hazards, modified exposure or new scientific uncertainties identified during the authorisation period and not previously assessed in the context of the original application. Under the assumption that the DNA sequence of the event in maize GA21 considered for renewal is identical to the corrected sequence of the originally assessed event, the GMO Panel concludes that there is no evidence in the renewal application EFSA-GMO-RX-005 for new hazards, modified exposure or scientific uncertainties that would change the conclusions of the original risk assessment on maize GA21.
Summary
Following the submission of application EFSA-GMO-RX-005 under Regulation (EC) No 1829/2003 1 from Syngenta Crop Protection NV/SA, the Panel on Genetically Modified Organisms of the European Food Safety Authority (GMO Panel) was asked to deliver a scientific opinion on the data submitted in the context of the renewal of authorisation application of the herbicide-tolerant genetically modified (GM) maize GA21. The scope of the renewal application EFSA-GMO-RX-005 is for food and feed uses, import and processing, but excludes cultivation within the European Union (EU).
In delivering its scientific opinion, the GMO Panel took into account application EFSA-GMO-RX-005, additional information provided by the applicant, scientific comments submitted by the Member States and relevant scientific publications. The data received in the context of the renewal application EFSA-GMO-RX-005 contained: post-market environmental monitoring reports, an evaluation of the literature retrieved by a systematic search, updated bioinformatics analyses, and additional documents or studies performed by or on behalf of the applicant. The GMO Panel assessed these data for possible new hazards, modified exposure or new scientific uncertainties identified during the authorisation period and not previously assessed in the context of the original application.
In conclusion, under the assumption that the DNA sequence of the event in maize GA21 considered for renewal is identical to the corrected sequence of the originally assessed event, the GMO Panel concludes that there is no evidence in the renewal application EFSA-GMO-RX-005 for new hazards, modified exposure or scientific uncertainties that would change the conclusions of the original risk assessment on maize GA21. In giving its scientific opinion to the European Commission, the Member States and the applicant, and in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003, EFSA has endeavoured to respect a time limit of 6 months from the acknowledgement of the valid application. As additional information was requested by the GMO Panel, the time limit of 6 months was extended accordingly, in line with Articles 6(1), 6(2), 18(1) and 18(2) of Regulation (EC) No 1829/2003.
According to Regulation (EC) No 1829/2003, this scientific opinion is to be seen as the report requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall opinion in accordance with Articles 6(5) and 18(5).
Terms of Reference as provided by the requestor
The GMO Panel was requested to carry out a scientific risk assessment on the data submitted in the context of a renewal of authorisation application for maize GA21 for food and feed uses, import and processing in accordance with Articles 11 and 23 of Regulation (EC) No 1829/2003.
Where applicable, any conditions or restrictions which should be imposed on the placing on the market and/or specific conditions or restrictions for use and handling, including post-market monitoring requirements based on the outcome of the risk assessment and, in the case of GMOs or food/feed containing or consisting of GMOs, conditions for the protection of particular ecosystems/environment and/or geographical areas, should be indicated in accordance with Articles 6(5)(e) and 18 (5) The GMO Panel was not requested to give an opinion on information required under Annex II to the Cartagena Protocol. Furthermore, the GMO Panel did not consider proposals for labelling and methods of detection (including sampling and the identification of the specific transformation event in the food/feed and/or food/feed produced from it), which are matters related to risk management.
2.
Data and methodologies
Data
The data for application EFSA-GMO-RX-005 provided by the applicant at the time of submission, or in reply to requests for additional information, are specified below.
In the context of this renewal application, no new sequencing study was submitted among the additional documents or studies performed by or on behalf of the applicant. The applicant clarified that the maize GA21 sequence considered in the context of this renewal application is the sequence originally submitted (EFSA, 2007) , corrected for sequencing errors consisting of one-base pair addition, a three-base pair deletion and a difference in the number of complete mepsps cassettes present within the insert which were already assessed by the GMO Panel (EFSA GMO Panel, 2015a) .
In accordance with the GMO Panel guidelines for renewal of applications of GM food and feed authorised under Regulation (EC) No 1829/2003 (EFSA GMO Panel, 2015b), the GMO Panel evaluated the data provided in the context of this maize GA21 renewal application under the assumption that the event sequence is identical to the corrected sequence of the event (EFSA GMO Panel, 2015a).
Post-market monitoring reports 5
Based on the outcome of the initial food and feed risk assessment, a post-market monitoring plan for monitoring of GM food/feed was not required by the authorising decision. The implementation of a postmarket environmental monitoring (PMEM) plan, consisting of a general surveillance plan to check for any adverse effects on the environment arising from maize GA21, was a condition for the authorisation. As no potential adverse environmental effects were identified in the environmental risk assessment (ERA) of maize GA21 (EFSA, 2007), case-specific monitoring was not considered necessary by the GMO Panel.
The applicant provided nine annual PMEM reports covering a reporting period from March 2008 to July 2016. The annual PMEM plans submitted by the applicant included (1) the description of a centralised system established by EuropaBio for the collection of information recorded by various operators (federations involved in maize (or bulk grain) import and processing) on any observed adverse effect(s) on human health and the environment arising from handling of maize possibly containing GA21; (2) the reports of the surveillance activities conducted by such operators; and (3) the review of relevant scientific peer-reviewed studies retrieved from literature searches.
The applicant provided an overall assessment of the general surveillance activities in the renewal dossier.
Systematic search and evaluation of literature 6
As part of the annual PMEM reports, nine separate literature searches were provided covering a reporting period from March 2008 till July 2016. Search terms and databases were not consistently used throughout the reports. Therefore, the applicant performed a systematic search of studies published between 1 June 2005 and 30 June 2016, relevant to the food/feed and environmental safety assessments of event maize GA21 and mutated 5-enol-pyruvyl-shikimate-3-phosphate-synthase (mEPSPS) protein, covering the authorisation period, and following the principles outlined in the EFSA guidance on the application of systematic review methodology for food and feed safety assessment (EFSA, 2010) .
The applicant searched several general and subject-specific databases to identify relevant studies. The search was limited to primary research peer-reviewed studies that were published in English. Altogether 859 studies were retrieved. After applying the eligibility/inclusion criteria defined a priori by the applicant, 16 relevant primary research studies were identified. Ten studies were identified by the applicant as relevant for the food and feed risk assessment and six for the ERA risk assessment (Appendix A).
Updated bioinformatic data 7
At the time of submission of the renewal dossier, the applicant provided a bioinformatics package for maize GA21 including an analysis of the insert and flanking sequences and an analysis of the potential similarity to allergens or toxins of the newly expressed proteins and of all possible open reading frames (ORFs) within the insert and spanning the junction sites. The bioinformatics package was based on the original sequence corrected for sequencing errors (EFSA GMO Panel, 2015a). The bioinformatics package also included an analysis of possible horizontal gene transfer (HGT).
Additional documents or studies provided by the applicant 8
In line with the renewal guidance requirements (EFSA GMO Panel, 2015b), the applicant provided an overview on the worldwide approvals of maize GA21 and a list containing the summaries of all studies performed by or on behalf of the applicant over the course of the authorisation period and not previously submitted to the European Union (EU) (Appendix B).
The relevance of the listed studies for molecular characterisation, human and animal safety and the environment was assessed by the applicant. The GMO Panel requested to the applicant on 30 June 2017 the full study reports of five of these studies considered potentially relevant for safety assessment. The applicant submitted the requested information on 6 July 2017.
Overall assessment as provided by the applicant 9
In line with the requirements listed in the renewal guidance (EFSA GMO Panel, 2015b), the applicant provided an overall assessment concluding that information provided in the application for renewal of the authorisation of maize GA21 for food and feed use and processing in the EU, do not change the outcome of the original risk assessment (EFSA, 2007).
Monitoring plan and proposal for improving the conditions of the original authorisation 10
The applicant indicated in the dossier that the environmental monitoring plan is appropriate and does not need any changes.
Methodologies
The GMO Panel assessed the application for the renewal of the authorisation of maize GA21 for food and feed uses, import and processing in accordance with Articles 11 and 23 of Regulation ( The comments raised by Member States are addressed in Annex G of EFSA's overall opinion 11 and were taken into consideration during the scientific risk assessment.
Assessment

Evaluation of the post-market environmental monitoring reports
During the general surveillance activities covering the authorisation period of maize GA21, no adverse effects were reported by the applicant.
3.2.
Evaluation of the systematic search and evaluation of literature
The GMO Panel assessed the 16 published studies listed in Appendix A and considered that none of them gave rise to any safety concern for human and animal health and the environment which would change the original risk assessment conclusions on maize GA21 (EFSA, 2007) .
Evaluation of the updated bioinformatic data
The results of the updated bioinformatics analyses on the corrected GA21 event sequence confirmed previous assessments (EFSA, 2007; EFSA GMO Panel, 2010a ,b, 2011 , 2015a that no known endogenous genes were disrupted by the insert. Analyses of the amino acid sequence of the newly expressed mEPSPS protein revealed no significant similarities to toxins and allergens. In addition, bioinformatics analyses of the newly created ORFs within the insert or spanning the junctions with genomic DNA revealed no significant similarities to toxins and allergens.
The sequence identity analysis of the regions of bacterial origin in maize GA21 did not identify elements with sufficient length and identity to support homologous recombination (EFSA GMO Panel, 2015a) . There is no information that would change the previous conclusion of the GMO Panel that the unlikely, but theoretically possible, horizontal transfer of recombinant genes from maize GA21 to bacteria does not raise any environmental safety concern.
3.4.
Evaluation of the additional documents or studies provided by the applicant
The GMO Panel evaluated the summary and/or the full study reports of the additional studies provided and listed in Appendix B. This new information did not raise any concern for human and animal health and the environment, which would change the original risk assessment conclusions on maize GA21.
3.5.
Evaluation of the overall assessment as provided by the applicant
The GMO Panel evaluated the overall assessment provided by the applicant and confirmed that there is no evidence in the renewal application RX-005 indicating new hazards, relevant changes in exposure or scientific uncertainties.
3.6.
Evaluation of the monitoring plan and proposal for improving the conditions of the original authorisation
The PMEM plan followed by the applicant consists mainly of general surveillance of imported GM maize plant material, including maize GA21. This general surveillance is coordinated by EuropaBio and implemented by selected operators (federations involved in maize import and processing). In addition, the applicant reviews relevant scientific publications retrieved from literature searches on an annual basis. As mentioned in Section 2.1.6, the applicant considers that this plan does not need any changes. The GMO Panel is of the opinion that the scope of the plan provided by the applicant is consistent with the scope of maize GA21 but reminds that monitoring is related to risk management, and thus the final adoption and implementation of the PMEM plan falls outside the mandate of EFSA.
Conclusions
Under the assumption that the DNA sequence of the event in maize GA21 considered for renewal is identical to the corrected sequence of the originally assessed event, the GMO Panel concludes that there is no evidence in the renewal application EFSA-GMO-RX-005 for new hazards, modified exposure or scientific uncertainties that would change the conclusions of the original risk assessment on maize GA21 (EFSA, 2007; EFSA GMO Panel, 2010a ,b, 2011 , 2015a . application EFSA-GMO-RX-005. 6) Letter from EFSA to applicant dated 30 June 2017 requesting additional information and stopping the clock. 7) Letter from applicant to EFSA received on 6 July 2017 providing additional information. 8) Email from EFSA to applicant dated 7 July 2017 re-starting the clock on 6 July 2017.
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